MSH2 Gene Muir-Torre Syndrome Genetic Test | 2,800 AED | DNA Labs UAE

Executive Summary & Core Metrics

This Next-Generation Sequencing (NGS) genetic test provides 99.9% diagnostic sensitivity for MSH2 mutations associated with Muir-Torre syndrome, a hereditary cancer condition. Processed at our ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139), the test includes VIP mobile phlebotomy and temperature-controlled cold-chain home collection (available daily from 8 AM to 11 PM). Each result is accompanied by a post-test telephonic clinical consultation. Direct insurance billing verification is available via WhatsApp +971 54 548 8731. Our facility operates under DHA License No. 1143 at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.

Test Overview & Methodology

The MSH2 gene NGS test sequences the entire coding region and splice junctions to detect germline mutations that confer a high lifetime risk of colorectal, endometrial, and sebaceous neoplasms. This comprehensive analysis supports early cancer surveillance, risk-reducing interventions, and cascade testing of at-risk relatives.

Feature	Our Test (MSH2 NGS)	Routine PCR / Sanger
Methodology	Next-Generation Sequencing (NGS) – Full gene coverage	Sanger Sequencing – Limited exon analysis
Turnaround Time	3–4 Weeks	4–6 Weeks
Price	2,800 AED	3,200 AED (est.)
DHA Compliance	DHA Licensed & ISO 9001:2015 Certified	Partial or non‑verified
Post‑Test Support	Telephonic clinical guidance included	Often not included

Physician Insight & Safety Protocols

“As a consultant medical geneticist, I emphasize that the MSH2 NGS test provides vital information for hereditary cancer risk assessment. However, a negative result does not eliminate the possibility of Muir-Torre syndrome if clinical suspicion remains high. Always discuss your results with a qualified genetics professional and adhere to recommended surveillance protocols.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory & Medication Safety

Medication Caution

Do not discontinue any prescribed medications without consulting your treating physician. This genetic test is intended for hereditary cancer risk assessment and does not replace acute medical evaluation or ongoing therapy.

Exclusion Criteria & ER Red Flags

Exclusion: Not intended for individuals under 18 years without a legal guardian’s written consent, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability and DHA regulations. Pregnant women should discuss the test with their obstetrician prior to participation.
ER Red Flags: If you experience new onset of unexplained weight loss, rectal bleeding, palpable abdominal mass, or severe fatigue, seek immediate medical evaluation. This genetic test is not a substitute for emergency care.

Patient FAQ & Clinical Guidance

1. What is the MSH2 gene test and who should consider it?

The MSH2 NGS test detects germline mutations causing Muir-Torre syndrome, enabling early cancer prevention and tailored screening. Individuals with a personal or family history of Lynch syndrome–related cancers (colorectal, endometrial, sebaceous skin tumors) at a young age, or those with multiple primary cancers, are ideal candidates. Genetic counseling is recommended before testing.

2. Does this test require genetic counseling?

Yes, genetic counseling is required before MSH2 testing to review family history and obtain informed consent. A certified genetic counselor will draw a pedigree and explain the implications of positive, negative, or variant of uncertain significance results. This aligns with DHA regulations and Federal Decree-Law No. 4 of 2016 on Medical Liability.

3. How long do results take and what support is provided afterward?

Results are available within 3–4 weeks. After the report is issued, you will receive a scheduled telephonic consultation with a clinical expert to interpret the findings and coordinate further surveillance or specialist referrals. A comprehensive written report is also provided.

UAE Regulatory & Data Privacy Adherence

Data Protection & Compliance

DNA Labs UAE operates under the strict framework of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed solely for the purpose of diagnostic interpretation. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA license (No. 1143) and ISO 9001:2015 certification ensure that every step of the testing process meets the highest international standards.

Clinical & Logistical Metadata

Test Name	MSH2 Gene Muir-Torre Syndrome Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood (EDTA) or Saliva
Methodology Used	Next-Generation Sequencing (NGS) – Full gene coverage
ICD-10-CM Code	Z15.09
LOINC Code	21636-9
DHA Facility License & Laboratory Address	DHA License No. 1143 \| DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE